Evidence map›Paper›PMID 34304928›Full record

ArticleVaccine2021

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.

Anne-Catherine Fluckiger, Barthelemy Ontsouka, Jasminka Bozic, Abebaw Diress, Tanvir Ahmed, Tamara Berthoud, Anh Tran, Diane Duque, Mingmin Liao, Michael McCluskie and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Advances in virus-like particle-based SARS-CoV-2 vaccines.Frontiers in cellular and infection microbiology · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. SARS-CoV-2 virus-like-particlesNanoscale advances · 2023
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Anne-Catherine FluckigerBionaria, 11Bis Rue de la Garenne, 69290 Saint-Genis-les-Ollières, France. Electronic address: afluckiger@vbivaccines.com.
Barthelemy OntsoukaVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Jasminka BozicVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Abebaw DiressVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Tanvir AhmedVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Tamara BerthoudVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Anh TranNational Research Council Canada, Department of Human Health Therapeutics, 100 Sussex Drive, Ottawa, ON K1A0R6, Canada.
Diane DuqueNational Research Council Canada, Department of Human Health Therapeutics, 100 Sussex Drive, Ottawa, ON K1A0R6, Canada.
Mingmin LiaoVaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 Canada.
Michael McCluskieNational Research Council Canada, Department of Human Health Therapeutics, 100 Sussex Drive, Ottawa, ON K1A0R6, Canada.
Francisco Diaz-MitomaVBI Vaccines, Cambridge, 222 Third Street, Cambridge 02142, MA, USA.
David E AndersonVBI Vaccines, Cambridge, 222 Third Street, Cambridge 02142, MA, USA.
Catalina SoareVBI Vaccines, 201-310 Hunt Club Road, Ottawa, ON K1V 1C1, Canada.
Variation Biotechnologies (Canada) · CANational Research Council Canada · CACentre de Recherche Astrophysique de Lyon · FRUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.

Indexed as

COVID-19Vaccines, Virus-Like ParticleAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCricetinaeHumansMiceSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Virus-Like ParticleImmunogenicityNeutralizing antibodiesSARS-COV-2VaccineVirus-like-particles

Identifiers

PMID34304928
PMCPMC8282453
OpenAlexW3184249037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.